


Compound 40 on page 25 and Compound 9 of Reference H is moot in view of the limitation of the compounds of Claim 1 to those wherein the R'OC<sub>2</sub>H group is in the p-position.

There will be submitted separately, when received from the client, a declaration of an expert comparing applicants' Compound 46 (Compound I) with the compound of Examples 3 and 8 of Reference H (Compound II). The experiments described in the declaration show that whereas Compound I at a dose of 0.1 mg/kg effected a 95% protection against myocardial injury, as indicated by the "S-T elevation" in the electrocardiogram of dogs, the known "Compound II" did not show any effect at all under the same conditions.

It is submitted these experiments rebuts any prima facie case of obviousness established by U.S. 3,674,840.

This application is submitted to be in condition for allowance, which action is respectfully solicited.

Respectfully submitted,

  
John L. White (17,746)  
Attorney for Applicants  
MILDEN & WHITE  
503 Crystal Mall Building 1  
1911 Jefferson Davis Highway  
Arlington, Virginia 22202  
Telephone: (703) 892-2200

JLW:jp

Filed: June 9, 1980